From regulatory limitations to new opportunities: real-life experience on the effectiveness of short courses of omalizumab in the treatment of chronic idiopatic urticaria.
Economic sustainability of long-term continuous treatment of antihistamine refractory chronic urticaria with omalizumab may be an issue. We assessed the efficacy of relatively short courses (5-6 months) of omalizumab in patients with chronic idiopathic urticaria. We retrospectively studied 40 patients (observed between June 2015 and January 2019) affected by moderate-severe chronic idiopathic urticaria refractory to anti-H1 antihistamines (up to fourfold doses). Omalizumab was administered every four weeks for 24 weeks, then for 20 weeks in case of a relapse of moderate-severe degree, then again for 24 weeks in case of a second relapse. Monthly clinical evaluations were performed. Mean disease severity significantly dropped after 1 month and further decreased thereafter, with 30 complete remissions after the first course of treatment. In 2-4 months, 18 patients had a relapse of moderate-severe degree. The profile of response to the second course of omalizumab was similar to the first. A third course was necessary for 7 patients. No adverse effects were recorded. Courses of 5-6 months of omalizumab may induce rapid significant improvement of urticaria and many prolonged complete remissions. In case of relapse, further courses show a similar profile of response, and may induce additional long-term complete remissions. This article is protected by copyright. All rights reserved.